The prognostic value of N-terminal proB-type natriuretic peptide
Lisa C Costello-Boerrigter* and John C Burnett Jr
Correspondence *Cardiorenal Research Laboratory, Guggenheim 915, Mayo Clinic and Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Email costello.lisa@mayo.edu
The roles of N-terminal proBNP, an inactive amino acid product of BNP prohormone cleavage, seem to be many-fold in heart disease. Here, Lisa C Costello-Boerrigter and John C Burnett Jr explore some of the ways in which this biomarker can aid diagnosis and prediction of prognosis in various cardiovascular diseases.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Natriuretic Peptides: An Update on Bioactivity, Potential Therapeutic Use, and Implication in Cardiovascular DiseasesAmerican Journal of Hypertension News and Views
RESEARCH
N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysisKidney International Original Article
Plasma N terminal pro-brain natriuretic peptide levels and its determinants in a multi-ethnic populationJournal of Human Hypertension Original Article
Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantationBone Marrow Transplantation Original Article
See all 21 matches for Research